Source: PMLiVE

Genmab: Genmab announces EC approval of Tivdak in recurrent or metastatic cervical cancer

Approximately 660,000 new cases of the disease were diagnosed globally in 2022 alone

Read full article »
Genmab's Competitors | Genmab's News | Genmab's Financials
Stay up-to-date with the latest news on Genmab
Annual Revenue
$1.0-5.0B
Employees
1.0-5.0K
Jan G. J. van de Winkel's photo - President & CEO of Genmab

President & CEO

Jan G. J. van de Winkel

CEO Approval Rating

99/100

Read more
Stay up-to-date with the latest news on Genmab